Curiosity Science

08/02/2026

Guillain-Barré syndrome strikes suddenly — the immune system attacks
the body's own nerves, causing rapid muscle weakness that can leave
patients unable to walk or even breathe unaided. For decades, the only
options have been IVIg or plasma exchange, both slow, intensive, and
only partially effective for many patients.

Now, a drug called tanruprubart (also known as ANX005) could become
the first targeted, disease-modifying therapy ever approved for GBS.
It's a first-in-class C1q monoclonal antibody, meaning it blocks a
single immune protein, C1q, shutting down the specific complement-
driven inflammatory pathway that damages nerves — delivered in one
30 mg/kg intravenous infusion, rather than repeated treatments over
several days.

In Phase 3 trials, patients treated with tanruprubart recovered faster
and more completely than those on standard care. The drug has already
received Fast Track and Orphan Drug status from regulators in both the
US and Europe, and Annexon, the company developing it, has now filed
its formal approval application with the European Medicines Agency.

Source: Annexon, Inc. / New Scientist (2026)

07/25/2026

Nearly every physical product around us — planes, cars, appliances —
starts life as a CAD model. AI can now sketch those models from a
simple 2D image, but the results are often too simplistic for real
engineering use.

MIT researchers built a system called GIFT that fixes this by teaching
AI from its own mistakes. Instead of feeding a model more random
training data, GIFT tests it repeatedly, zeroes in on the "near-miss"
attempts where it's right only about half the time, corrects them, and
turns those corrections into targeted new training data.

The result: significantly more accurate 3D CAD models, using only
about 20% of the computing power required by competing methods — a
step toward AI tools engineers can actually trust for rapid
prototyping.

Source: MIT News (2026) / International Conference on Machine Learning
Paper: "GIFT: Bootstrapping Image-to-CAD Program Synthesis via
Geometric Feedback"

07/22/2026

07/19/2026

Microplastics are now found in our blood, organs, and even brain
tissue — and until now, there's been little we could do to remove
them. A new study suggests a surprisingly simple fix: a supplement
made from dead bacteria.

Researchers found that the bacteria's naturally rough surface
attracts microplastic particles, binding to them in the gut and
preventing their absorption into cells — potentially helping the
body flush them out before they spread further.

It joins a growing list of biological approaches, from probiotic
strains in fermented foods to natural fibers, that scientists hope
could one day help humans clear the plastic quietly accumulating
inside us.

Source: New Scientist (2026)

07/17/2026

For decades, brain implants have offered incredible precision — but
they require risky surgery and cost so much that fewer than 100
people worldwide have ever used one. Now, Carnegie Mellon researchers
have found a way to get similar control without opening the skull.

The challenge: human brains learn through trial and error, while AI
learns through rigid math — and the two often fall out of sync.
Bin He's team built the first framework that unifies both, using
tactile feedback to guide the user while the algorithm adapts
alongside them.

The result: 31 completely untrained participants hit up to 86%
control accuracy on their very first attempt — performance rarely
seen without weeks of practice, and a major step toward noninvasive,
surgery-free brain-computer interfaces for paralysis, prosthetics,
and rehabilitation.

Source: Nature Communications (2026), Carnegie Mellon University
DOI: 10.1038/s41467-026-75435-5

07/10/2026

Spinal cord injury affects millions of people worldwide, and for
those living with chronic injury, there is still no treatment
that can meaningfully restore lost function. That may be starting
to change.

Researchers at Keio University in Japan have presented promising
new preclinical results using a specialized type of neural stem
cell — called gliogenic neural stem/progenitor cells (gNS/PCs) —
transplanted into the injured spinal cord. These cells are
designed to remyelinate surviving but damaged nerve fibers that
have gone silent, potentially restoring signalling along pathways
that still physically exist but can no longer conduct.

The team has already completed the world's first clinical trial
of this cell type in subacute spinal cord injury patients, where
it showed a safe profile. They now plan to begin recruiting
chronic SCI patients in 2027 — a harder target, given the
scarring and biological barriers that build up over time.

Source: ISSCR Annual Meeting 2026 / Keio University

07/06/2026

NASA astronaut Don Pettit designed a zero-gravity coffee cup so
astronauts could finally drink coffee from an open cup instead of a
sealed pouch with a straw. In microgravity, liquids don't pour — they
cling and float — so the cup relies on surface tension and a carefully
shaped, teardrop-style channel to wick coffee along its edge and into
the drinker's mouth.

Beyond convenience, the design solved a surprisingly important problem:
astronauts could finally smell their coffee again, something impossible
with a sealed bag. Pettit's original prototype, built from scrap plastic
and tape, was later refined by fluid physicist Mark Weislogel into the
cup used on the ISS today.

Source: NASA / International Space Station
Science